Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


loader
  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • v114 report

    V114

    Read More

    Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.

    December 21, 2018
    Find out more
  • VB-111

    Read More

    VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

    (bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

    from the Phase III GLOBE study.

    April 13, 2016
    Find out more
  • Afinitor

    Read More

    Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.

    March 6, 2019
    Find out more
  • RSV preF vaccine

    Read More

    Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.

    October 5, 2018
    Find out more
  • kynamro_report

    Kynamro

    Read More

    Kynamro (mipomersen sodium) was the first antisense therapy to enter the dyslipidemia market. It is marketed by Kastle Therapeutics and is approved in the US for the treatment of homozygous familial hypercholesterolemia (HoFH).

    June 22, 2018
    Find out more
  • Sotagliflozin

    Read More

    Sotagliflozin (Lexicon/Sanofi) is an orally administered drug currently being investigated for the treatment of type 1 and type 2 diabetes. It is a dual inhibitor of the sodium-glucose cotransporter-1 (SGLT-1) and SGLT-2 transporters.

    November 7, 2017
    Find out more
  • Tymlos

    Read More

    Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.

    March 9, 2018
    Find out more
  • OncoVAX

    Read More

    OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient’s own cancer cells to prevent tumor progression after surgery.

    December 11, 2017
    Find out more
  • Toujeo

    Read More

    Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot.

    November 7, 2017
    Find out more
  • Tezacaftor/Ivacaftor

    Read More

    Vertex’s tezacaftor (formerly known as VX-661) is a CFTR corrector compound being investigated as an adjunct to Vertex’s other marketed and developmental CFTR-targeting products. The drug’s initial development is as part of a fixed-dose combination with the CFTR potentiator ivacaftor (Vertex), which was approved with the brand name Kalydeco in January 2012.

    September 14, 2017
    Find out more
  • NovoEight

    Read More

    NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.

    May 4, 2018
    Find out more
  • Prolia

    Read More

    Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis.

    March 9, 2018
    Find out more
  • Ultibro

    Read More

    Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

    chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

    markets boost its overall clinical and commercial attractiveness.

    April 11, 2016
    Find out more
  • Taltz

    Read More

    Taltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17.

    May 18, 2018
    Find out more
  • solithromycin

    Read More

    Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.

    June 19, 2015
    Find out more
Page 2 of 41
Page 2 of 41‹1234›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top